Safety and Initial Feasibility of Using the Neurolyser for Facet Related Low Back Pain

Study design: Prospective, single arm

Timeline: six month enrollment period and 12 months follow-up period.

Sites: The study will be conducted at McGill University.

Study population: Ten adult patients diagnosed with facet related low back pain.

Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of facet related low back pain.

Safety would be evaluated by the incidence and severity of treatment related adverse events Efficacy would be evaluated by the changes in average pain score and Rolland Morris Disability Questionnaire between baseline and 6 months.

Inclusion criteria

• Adult male and females, legally able and willing to participate in the study and come for follow-up visits
• Able and willing to fill the study forms and to communicate with investigator
• Patient with uni or bilateral lumbar facetogenic pain of > 6 months duration
• Patients presenting with a) a positive (>70% pain relief) to a previous L1 to L5 lumbar medial branch block and / or b) with a positive (>70% pain relief) to a previous lumbar facet thermal RF denervation within the last 6 months)
• Average pain score of 4 or higher in the last month, (on a scale of 0 to 10)

Exclusion criteria

• Pregnant or breastfeeding patient
• Patients younger than 18 or older than 80 years
• Patients presenting with neurological deficits (including lumbosacral radiculopathy but not radicular pain).
• History of spine surgery
• Presence of metal hardware at the lumbosacral spine
• Lumbar spine pathology that may increase procedural risk and / or influence symptoms and / or generate unrelated adverse event, (per the discretion of the study PI)
• Patients unable to understand and complete the research questionnaires in English or French
• Any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcome.
• Patient with extensive scarring in the skin and tissue overlying the treatment area.
• Patients enrolled in or planned to be enrolled in another clinical trial during the duration of this research project